This newsletter presents you the following key sessions:
1. Improved PFS and OS for switch maintenance with ramucirumab plus paclitaxel compared
to continuation of chemotherapy in advanced HER2-negative gastric or GEJ cancer:
results of phase III ARMANI trial
2. Interim analysis of Phase II trial REGINA: promising pathological CR rates after neoadjuvant
regorafenib, nivolumab and short-course radiotherapy in stage II-III rectal cancer
3. First-line treatment with nivolumab plus ipilimumab improves the health-related quality of
life in patients with MSI-H/dMMR mCRC compared to chemotherapy
4. POCHI trial: combining pembrolizumab with standard therapy is effective in patients with
pMMR/MSS mCRC and high tumor lymphocyte infiltration